Pipeline

Novel biologics portfolio & partnerships

We currently have a range of programs in our pipeline, the most advanced of which is our humanized antagonist anti-CD89. We aim to progress our programs to proof-of-concept studies in the clinic. If you are interested in finding out more please contact us.

Humanized antagonist anti-CD89

Auto-antigen specific IgA antibodies are associated with disease severity in over a dozen of different auto-immune indications and therefore disease-specific IgA antibodies were selected as companion diagnostic for the development of an innovative therapeutic.

A novel approach to pathogenic neutrophils

The anti-CD89 (FcαRI) program focuses on antagonizing the IgA receptor CD89 for the treatment of IgA-mediated diseases and the prevention of IgA-mediated pathogenic neutrophilic tissue damage. Neutrophils are part of the innate immune system and are the most ignored cell type of the immune system, but play a devastating role in many auto-immune diseases. Our novel approach is unique in both its target and in its therapeutic potential for neutrophilic-driven diseases, in which treatment options are severely lacking. A significant proportion of auto-immune patients who are not responding to TNF inhibitors have high neutrophil involvement in the disease accompanied by high auto-antigen specific IgA responses. Beyond neutrophil CD89 is also expressed on monocytes, macrophages and eosino-phils which upon IgA binding contribute to the inflammatory response that can also be inhibited by the antagonist anti-CD89 antibody.

The candidate antibodies being developed by JJP Biologics can prevent the IgA-mediated activation of the immune system and inhibit the release of chemo-attractive signals and pathogenic molecules, making them unique in their class. Furthermore, as companion diagnostic for patient stratification and personalized medicine, auto-antigen IgA antibodies which in most auto-immune disease are already embedded in daily clinical diagnosis of patients.

If you are interested in licensing our anti-CD89 therapeutic please contact us.

Undisclosed immuno-oncology antibody

The level of PD-L1 expression on tumours is being used as companion diagnostic to select patients for the treatment with the highly successful anti-PD1 antibodies. In analogy with the PD-L1-PD1 axis, we have selected another checkpoint inhibitor receptor expressed on various tumours and for which the level of expression highly correlates to poor prognosis and therefore is selected to serve as companion diagnostic for the current program.

A novel approach to pathogenic neutrophils

Our validated expertise in immunotherapy prompted the discovery and generation of innovative antibodies to new checkpoint inhibitor targets. This target was selected because of its high tumour expression, accompanied by a poor prognosis and immune suppressive tumour microenvironment. Similar to the PD1-PD-L1 axis, tumour expression of our novel target can be used as companion diagnostic for a personalized medicine strategy. This highly selective molecule blocks the regulatory interactions of the target with the patient’s immune system, while leaving Its stimulatory capacity untouched.